Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific share transaction rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific increase in notional share interests for Mr. A P Witty.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction under the Disclosure and Transparency Rule 3.1.4R(1)(a) involving the re-investment of dividends paid on July 7, 2011, at a price of 1359.50 pence per share.
Important Facts for Investors
- Transaction Type: Notification of an increase in notional interests in Ordinary shares for Mr. A P Witty under the 2009 Deferred Annual Bonus Plan.
- Share Details: Acquisition of 375 shares via personal contribution and 375 shares via company matching contribution.
- Transaction Price: 1359.50 pence per share.
- Dividend Context: The transaction followed the re-investment of dividends paid to shareholders on July 7, 2011.
- Financial Data: This filing does not contain quarterly or annual financial performance data.